Five years later: re-examining the financial burden of boosting with Norvir.
Marquez
Carina
C
Guglielmo
B Joseph
BJ
Klausner
Jeffrey D
JD
D003362:Cost-Benefit Analysis; D004345:Drug Industry / Q000331:legislation & jurisprudence; D017320:HIV Protease Inhibitors / Q000191:economics*; D006801:Humans; D019438:Ritonavir / Q000191:economics*; D014481:United States
D017320:HIV Protease Inhibitors; D019438:Ritonavir